论文部分内容阅读
[目的 ]探讨游离前列腺特异性抗原 (F -PSA)、总前列腺特异性抗原 (T -PSA)及F -PSA和T -PSA比值 (F/T) ,对良性前列腺增生 (BPH)和前列腺癌 (PCa)患者的鉴别价值。 [方法 ]采用微粒子酶免疫化学发光技术 ,测定 32例健康体检者、12 0例BPH患者和 32例PCa患者的血清F-PSA、T -PSA ,并计算其比值F/T。 [结果 ]正常对照组、BPH组与PCa组F -PSA依次为 (0 .4± 0 .3)、(2 .3± 2 .4 )和 (5 .9± 5 .7) μg/L ,T -PSA依次为 (1.5± 1.5 )、(11.7± 8.8)和 (33.9± 2 9.5 ) μg/L ,各组间差异显著 (P <0 .0 1)、F/T值BPH组高于PCa组 ,但标准差过大未有显著性差异(P >0 .0 5 )。在T -PSA诊断灰区 (4.0～ 2 5 .0 μg/L)中BPH组F/T值高于PCa组 (P <0 .0 5 ) ,并且以T -PSA >4 .0 μg/L、F/T比值 <15 .0 %为界值时效果较好。 [结论 ]联合应用T -PSA、F -PSA及F/T诊断PCa明显优于单用T -PSA。
[Objective] To investigate free prostate-specific antigen (F-PSA), total prostate-specific antigen (T-PSA) and F-PSA and T-PSA ratio (F/T) for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) The differential value of the patient. [Methods] The serum F-PSA and T-PSA in 32 healthy subjects, 120 BPH patients and 32 PCa patients were measured by using microparticle enzyme immunochemiluminescence technique, and the ratio F/T was calculated. [Results] The F-PSA of normal control group, BPH group and PCa group was (0. 4 ± 0.3), (2.3 ± 2. 4), and (5.9 ± 5. 7) μg/L, respectively. T-PSA levels were (1.5 ± 1.5), (11.7 ± 8.8), and (33.9 ± 29.5) μg/L, respectively. There were significant differences between groups (P <0.01), and F/T values in BPH group were higher than those in PCa. However, there was no significant difference in the standard deviation (P > 0.05). In the T-PSA diagnostic grey area (4.0 to 25.0 μg/L), the F/T value of the BPH group was higher than that of the PCa group (P <0.05), and the T-PSA was >4.0 μg/L. When the F/T ratio <15.0 % is the demarcation value, the effect is better. [Conclusion] The combined use of T-PSA, F-PSA and F/T for the diagnosis of PCa was significantly better than that of T-PSA alone.